Cargando…

Glycosides of Nadifloxacin—Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus

The increase in the number of bacteria that are resistant to multiple antibiotics poses a serious clinical problem that threatens the health of humans worldwide. Nadifloxacin (1) is a highly potent antibacterial agent with broad-spectrum activity. However, its poor aqueous solubility has limited its...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutchins, Mark, Bovill, Richard A., Stephens, Peter J., Brazier, John A., Osborn, Helen M. I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912027/
https://www.ncbi.nlm.nih.gov/pubmed/35268604
http://dx.doi.org/10.3390/molecules27051504
_version_ 1784666998778626048
author Hutchins, Mark
Bovill, Richard A.
Stephens, Peter J.
Brazier, John A.
Osborn, Helen M. I.
author_facet Hutchins, Mark
Bovill, Richard A.
Stephens, Peter J.
Brazier, John A.
Osborn, Helen M. I.
author_sort Hutchins, Mark
collection PubMed
description The increase in the number of bacteria that are resistant to multiple antibiotics poses a serious clinical problem that threatens the health of humans worldwide. Nadifloxacin (1) is a highly potent antibacterial agent with broad-spectrum activity. However, its poor aqueous solubility has limited its use to topical applications. To increase its solubility, it was glycosylated herein to form a range of trans-linked (3a-e) and cis-linked (7a,b) glycosides, each of which was prepared and purified to afford single anomers. The seven glycoside derivatives (3a-e, 7a,b) were examined for potency against eight strains of S. aureus, four of which were methicillin-resistant. Although less potent than free nadifloxacin (1), the α-L-arabinofuransoside (3a) was effective against all strains that were tested (minimum inhibitory concentrations of 1–8 μg/mL compared to 0.1–0.25 μg/mL for nadifloxacin), demonstrating the potential of this glycoside as an antibacterial agent. Estimation of Log P as well as observations made during preparation of these compounds reveal that the solubilities of the glycosides were greatly improved compared with nadifloxacin (1), raising the prospect of its use in oral applications.
format Online
Article
Text
id pubmed-8912027
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89120272022-03-11 Glycosides of Nadifloxacin—Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus Hutchins, Mark Bovill, Richard A. Stephens, Peter J. Brazier, John A. Osborn, Helen M. I. Molecules Article The increase in the number of bacteria that are resistant to multiple antibiotics poses a serious clinical problem that threatens the health of humans worldwide. Nadifloxacin (1) is a highly potent antibacterial agent with broad-spectrum activity. However, its poor aqueous solubility has limited its use to topical applications. To increase its solubility, it was glycosylated herein to form a range of trans-linked (3a-e) and cis-linked (7a,b) glycosides, each of which was prepared and purified to afford single anomers. The seven glycoside derivatives (3a-e, 7a,b) were examined for potency against eight strains of S. aureus, four of which were methicillin-resistant. Although less potent than free nadifloxacin (1), the α-L-arabinofuransoside (3a) was effective against all strains that were tested (minimum inhibitory concentrations of 1–8 μg/mL compared to 0.1–0.25 μg/mL for nadifloxacin), demonstrating the potential of this glycoside as an antibacterial agent. Estimation of Log P as well as observations made during preparation of these compounds reveal that the solubilities of the glycosides were greatly improved compared with nadifloxacin (1), raising the prospect of its use in oral applications. MDPI 2022-02-23 /pmc/articles/PMC8912027/ /pubmed/35268604 http://dx.doi.org/10.3390/molecules27051504 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hutchins, Mark
Bovill, Richard A.
Stephens, Peter J.
Brazier, John A.
Osborn, Helen M. I.
Glycosides of Nadifloxacin—Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus
title Glycosides of Nadifloxacin—Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus
title_full Glycosides of Nadifloxacin—Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus
title_fullStr Glycosides of Nadifloxacin—Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus
title_full_unstemmed Glycosides of Nadifloxacin—Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus
title_short Glycosides of Nadifloxacin—Synthesis and Antibacterial Activities against Methicillin-Resistant Staphylococcus aureus
title_sort glycosides of nadifloxacin—synthesis and antibacterial activities against methicillin-resistant staphylococcus aureus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912027/
https://www.ncbi.nlm.nih.gov/pubmed/35268604
http://dx.doi.org/10.3390/molecules27051504
work_keys_str_mv AT hutchinsmark glycosidesofnadifloxacinsynthesisandantibacterialactivitiesagainstmethicillinresistantstaphylococcusaureus
AT bovillricharda glycosidesofnadifloxacinsynthesisandantibacterialactivitiesagainstmethicillinresistantstaphylococcusaureus
AT stephenspeterj glycosidesofnadifloxacinsynthesisandantibacterialactivitiesagainstmethicillinresistantstaphylococcusaureus
AT brazierjohna glycosidesofnadifloxacinsynthesisandantibacterialactivitiesagainstmethicillinresistantstaphylococcusaureus
AT osbornhelenmi glycosidesofnadifloxacinsynthesisandantibacterialactivitiesagainstmethicillinresistantstaphylococcusaureus